re: Ann: Allied's Herpes Vaccine Progress... AHZ is just warming up.
It's great to see todays announcement but this will be a cost centre for a little while yet, although AHZ have sufficient funding for the Phase I trial.
The Cardiocel announcement will be the kicker for me in the short term. This is whats going to bring in the revenue and drive the price for a fundamental perspective nearterm.
Any vaccine results released along the way will be great and could well excite the media and market, but any drug will be at least 3 years away yet.
But Cardiocel revenues could be very substantial indeed. $200m pa. within 2-3 years. That would suggest AHZ has multibagger stock potential.
The vaccines are the jam on top, and hopefully a very thick layer of jam($6 billion p.a market).
Ann: Allied's Herpes Vaccine Progresses to Ph, page-10
-
- There are more pages in this discussion • 84 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.20 |
Change
-0.290(2.32%) |
Mkt cap ! $257.9M | |||
| Open | High | Low | Value | Volume |
| $12.49 | $12.50 | $11.80 | $396.0K | 32.70K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 923 | $11.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.20 | 1821 | 1 |
View Market Depth
| Last trade - 16.10pm 30/09/2024 (20 minute delay) ? |
| AVR (ASX) Chart |